None
Quote | Csl Ltd (OTCMKTS:CMXHF)
Last: | $192.75 |
---|---|
Change Percent: | 2.22% |
Open: | $193.6 |
Close: | $192.75 |
High: | $193.6 |
Low: | $192.75 |
Volume: | 358 |
Last Trade Date Time: | 07/25/2024 03:00:00 am |
News | Csl Ltd (OTCMKTS:CMXHF)
2024-06-21 15:50:11 ET Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to ente...
2024-06-11 13:59:31 ET Summary iShares MSCI Australia ETF provides targeted exposure to the Australian equities market, with a focus on large- and mid-cap companies. The EWA fund's top holdings include BHP Group, Commonwealth Bank of Australia, CSL Ltd., National Australia Bank, a...
Message Board Posts | Csl Ltd (OTCMKTS:CMXHF)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CMXHF News Article - Danish Medicines Council Grants Approval for CSL Behring's Respre | whytestocks | investorshangout | 01/24/2020 7:55:42 PM |
Emylers: CMXHF Financials 07/16/2014 06:28:27 CSL Ltd. Period Ending Total Revenue Cost of Revenue G | Emylers | investorshangout | 07/16/2014 11:28:24 AM |
Stock_Tracker: Latest Csl Ltd (CMXHF) Headlines Between 2012-2016, the Global Telecom Industry to Wi | Stock_Tracker | investorshangout | 03/09/2014 2:21:55 PM |
chartguy89: CMXHF 64.935 Stock Charts $CMXHF 1 Month Chart | chartguy89 | investorshangout | 03/06/2014 6:00:23 PM |
chartguy89: CMXHF Stock Charts Last: +1.05 Monday, February 24, 2014 at 8:04:48 PM $CMXHF 1 | chartguy89 | investorshangout | 02/25/2014 1:04:59 AM |
News, Short Squeeze, Breakout and More Instantly...
Csl Ltd Company Name:
CMXHF Stock Symbol:
OTCMKTS Market:
New York, United States (ABN Newswire) - OTC Markets Group Inc. (OTCMKTS:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited (ASX:CSL) (OTCMKTS:CSLLY), a leading global biotechnology company with a dynamic portfolio of lifesaving medicine...
HATTERSHEIM AM MAIN, Germany , Jan. 24, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 Antitrypsin (AAT) therapy and Respreeza® as standard treatment for ...